SCHEDULE: Fairmount Boosts Viridian Therapeutics Stake to 15.14%

Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC increased their beneficial ownership in Viridian Therapeutics, Inc. to 15.14% through a recent public offering.

Summary

• Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC (Reporting Persons) jointly filed Amendment No. 7 to Schedule 13D for Viridian Therapeutics, Inc.
• The Reporting Persons now beneficially own an aggregate of 16,025,330 shares of Viridian Therapeutics, Inc. common stock, representing 15.14% of the outstanding class.
• This ownership includes 3,914,458 shares of common stock and 12,110,872 shares of common stock issuable upon conversion of Series A and Series B Preferred Stock.
• The conversion of preferred stock is subject to a beneficial ownership limitation of 19.99% of the outstanding common stock.
• The percentage is based on 105,830,130 shares of Common Stock outstanding as of October 23, 2025.
• On October 23, 2025, Fairmount Healthcare Fund II LP (Fund II) purchased 454,545 shares of common stock in an underwritten public offering for an aggregate price of $9,999,990.00, at $22 per share.
• The shares were acquired for investment purposes using working capital.
• Fund II entered into a 60-day lock-up agreement, restricting sales without consent from the underwriters.

Sentiment

Score: 7

Explanation: The increased stake by a sophisticated institutional investor, Fairmount, through a public offering suggests a positive view on Viridian Therapeutics' prospects. While a lock-up exists, it's standard for such offerings. The filing itself is a routine disclosure of an investment decision.

Positives

• Increased investment by a significant institutional investor (Fairmount) indicates confidence in Viridian Therapeutics, Inc.'s prospects.
• The purchase was part of an underwritten public offering, suggesting market demand for Viridian's shares and successful capital raise for the company.

Negatives

• The 60-day lock-up agreement restricts Fund II from selling newly acquired shares, potentially limiting liquidity for that specific block of shares in the short term.

Risks

• The beneficial ownership limitation of 19.99% on the conversion of Series A and Series B Preferred Stock could restrict the full conversion of preferred shares into common stock if the threshold is met.
• The 60-day lock-up agreement prevents the reporting person from selling shares, which could impact their ability to react to market changes during that period.

Future Outlook

The filing primarily details a past transaction and current ownership structure, not explicit forward-looking statements or guidance from the company or the reporting persons regarding the company's future performance. The stated purpose of the transaction is for investment purposes.

Industry Context

This filing indicates an institutional investor increasing its stake in a therapeutics company. This could reflect a broader trend of investment in the biotechnology or pharmaceutical sector, potentially driven by specific pipeline developments or market opportunities for Viridian Therapeutics. The participation in a public offering suggests capital raising activity within the industry.

Stakeholder Impact

• Shareholders: The increased institutional ownership could be seen as a vote of confidence, potentially stabilizing or supporting the stock price. The public offering itself dilutes existing shareholders, but also provides capital to the company.
• Company (Viridian Therapeutics): The capital raised from the public offering provides additional funding for operations, research, and development.

Next Steps

• The 60-day lock-up period for Fund II's newly acquired shares will expire, after which they will be free to sell without underwriter consent.

Key Dates

Recommendation

The filing indicates a significant institutional investor, Fairmount, has increased its stake in Viridian Therapeutics through a public offering, signaling confidence. However, this is an ownership disclosure, not a performance report. While the investment is a positive signal, it doesn't provide new fundamental data to warrant a 'buy' or 'strong buy' recommendation without further analysis of the company's financials and strategic outlook. The 60-day lock-up is a standard practice and doesn't inherently change the investment thesis. A 'hold' is appropriate as the filing confirms an institutional vote of confidence but lacks new operational or financial catalysts for a stronger recommendation.

Keywords

Viridian Therapeutics, Fairmount Funds Management, Fairmount Healthcare Fund II, Schedule 13D, Beneficial Ownership, Common Stock, Preferred Stock, Investment, Public Offering, Equity Stake, Biotechnology, Pharmaceuticals